A new activator of esterase D decreases blood cholesterol level through ESD/JAB1/ABCA1 pathway. Issue 6 (7th December 2020)

• Record Type: Journal Article
• Authors: Chen, Xinpeng; Su, Le; Yang, Yuejun; Qv, Jingyao; Wei, Tiandi; Cui, Xiaoling; Shao, Jing; Liu, Shuyan; Xu, Zhigang; Zhao, Baoxiang; Miao, Junying
• Is Part Of: Journal of cellular physiology. Volume 236:Issue 6(2021)
• Page Start: 4750
• Page End: 4763
• Publication Date: 2020-12-07
• Subjects: ABCA1 -- cholesterol -- ESD -- FPD5 -- JAB1; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.30196
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Excessively high cholesterol content in the blood leads to nonalcohol fatty liver disease (NAFLD) and arteriosclerosis. Although there are increasing publications and patent applications to lower blood cholesterol with small chemical molecules, limited effective drugs can be available in clinic. It is necessary to uncover new targets and drugs to alleviate high cholesterol. Esterase D (ESD) is abundant in liver and it remains unknown about its role in cholesterol metabolism. Here we reported that small chemical molecule fluorescigenic pyrazoline derivative 5 (FPD5), a new ESD activator, could effectively reverse high blood cholesterol level and prevent fatty liver and arteriosclerosis in apoE −/− mice fed the high‐fat diet. We also observed that FPD5 could reduce oxidized low density lipoprotein (oxLDL)‐induced formation of foam cells. To further investigate the mechanism of FPD5 action on blood cholesterol modulation, we found that ESD trigged by FPD5 was aggregated in lysosome and interacted with Jun activation domain binding protein 1 (JAB1). ESD served as a deacetylase to remove Thr89 acetylation of JAB1 and increased its activity; thus, promoting the ATP‐binding cassette transporters A1 (ABCA1) to accelerate cholesterol efflux. Our findings demonstrate that FPD5 decreases blood cholesterol level to ameliorate NAFLD and arteriosclerosis through ESD/JAB1/ABCA1 pathway, and ESD functions as a novel nonclassical deacetylase that hydrolyzes serine/threonine acetyl group. Our findings not only highlight that FPD5 may be a pioneer drug for alleviating blood cholesterol but also indicate that ESD is a potential drug target that promotes cholesterol metabolism. Abstract : Esterase D (ESD) activator named FPD5 decreases blood cholesterol level to ameliorate nonalcohol fatty liver disease (NAFLD) and arteriosclerosis through ESD/JAB1/ABCA1 pathway, and ESD functions as a novel nonclassical deacetylase that hydrolyzes serine/threonine acetyl group.